Skip to content

    Cipla Limited

    CIPLA
    Healthcare·28 Jan 2025
    Management Summary

    Cipla reported its highest-ever quarterly revenue of ₹7,073 crores, up 8% YoY, and an all-time high EBITDA margin of 28% for Q3 FY25. Growth was robust across India, North America, Africa, and EMEU, with strong traction in branded prescriptions and Albuterol market share. However, launch delays for key US assets like Abraxane and ongoing supply issues for Lanreotide were noted. Management clarified that the Q3 margin is not sustainable for future quarters and provided updated FY25 guidance for EBITDA and ETR.

    Highlights

    5
    • Highest ever quarterly revenue of ₹7,073 crores, marking an 8% YoY growth.

    • All-time high EBITDA margin of 28%, driven by favorable mix and cost phasing.

    • Strong performance in key geographies: One India (10% YoY), One Africa (9% YoY USD terms), and EMEU (20% YoY USD terms).

    • Albuterol market share reached 21%, contributing to North America's $226 million quarterly revenue.

    • Goa facility cleared by US FDA with VAI Classification, derisking future launches.

    Concerns

    4
    • Lanreotide supply issues impacted revenue, though normalization is expected by end of Q4 FY25.

    • Abraxane launch delayed to H2 FY26 due to regulatory clearance and manufacturing ramp-up post-approval.

    • Q3 EBITDA margin of 28% is not sustainable for future quarters due to seasonal respiratory uptick and mix effects.

    • Virgonagar and Medispray facilities received 483 observations from US FDA, with official classification awaited.

    What Changed3

    vs Q4 FY25

    Guidance items2 → 5 (+3)Risks discussed2 → 4 (+2)Q&A highlights3 → 8 (+5)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹7,073 Cr+8%YoY
    2. 02EBITDA Margin28%+1.8%YoY
    3. 03PAT₹1,571 Cr
    4. 04R&D Investment₹360 Cr
    5. 05R&D % of Revenue5%

    Segment breakdown

    One India
    10% Revenue Growth
    North America
    226 Mn Revenue
    One Africa
    9% Revenue Growth10% Revenue Growth (INR)
    EMEU
    20% Revenue Growth22% Revenue Growth (INR)
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹466 crores

    Liquidity

    Cash ₹8,947 crores

    Healthy net cash position as of December 31, 2024.

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    higher than 24.5% to 25.5%
    High
    Tax
    Effective Tax Rate (ETR)
    27% to 28%
    High
    Shareholder Returns
    Dividend Payout Ratio
    about 30%
    High
    Revenue
    Top Line Growth
    grow
    Medium
    R&D Spend
    R&D % of Revenue
    5% to 6%
    High

    Lanreotide Supply Normalization

    by end of March / Q1 FY26
    Current50-60% of normal supply
    Target100% normal supply, full capacity from partner

    Why it matters

    Ensuring full supply of Lanreotide is crucial for recovering lost revenue and meeting market demand.

    The business is on its way to resolve the supply issues related to Lanreotide and come back to normalized supply levels towards the end of Q4. ... we are probably about 50%, 60% there and what is not there is rapidly the partners rapidly working to bring that on line as well. So, our expectation right now is that the full capacity of the partner probably comes in, starts getting delivered pretty much from the end of March and so that allows us the ability to potentially see the ramp up in Q1 as also gives us the ability to build a little bit of inventory.

    How to verify

    key_financials.segment_breakdown[name='North America'].metrics[label='Revenue']

    Risks & concerns

    4
    RiskSeverity

    US FDA 483 observations at Virgonagar and Medispray facilities

    Virgonagar received eight 483 observations, Medispray received one; official classification awaited for both. Management is working on improving quality systems.Management acknowledged

    medium

    Delays in key US product launches (Advair, Abraxane)

    Advair launch signaled for H2 FY26, Abraxane for H2 FY26, primarily due to pending regulatory approvals and manufacturing ramp-up post-approval.Management acknowledged

    medium

    Lanreotide supply disruption impacting revenue

    Supply issues are being resolved, with normalization expected by end of Q4 FY25 and full capacity from partner by end of March.Management acknowledged

    medium

    Non-sustainability of Q3 EBITDA margin

    The 28% EBITDA margin in Q3 was influenced by seasonal respiratory uptick and favorable mix, and is not expected to be consistent in future quarters.Management acknowledged

    low

    Q&A highlights

    8

    “Revlimid is sequentially more or less the same. I think there's no increase in Revlimid quarter-on-quarter sequentially. On the rest of the assets, Advair, we have still not launched and we're signaling half two launch from the US facility. On Abraxane, we have a definite launch at least by the end of this next year and a few months after approval.”

    Clarifies the status and delayed timelines for critical US product launches, impacting future US revenue growth.

    asked by Saion Mukherjee

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q3 FY25 Performance and Geographic Growth

    Cipla delivered its highest-ever quarterly revenue of ₹7,073 crores, marking an 8% year-on-year growth. This was supported by robust performance across key geographies, with the One India business growing 10% YoY, One Africa achieving 9% YoY growth in USD terms (21% in ZAR terms for South Africa), and EMEU recording a strong 20% YoY growth in USD terms. The company's chronic mix in Branded Prescriptions improved to 61.5% as per IQVIA MAT December '24, and it added five brands with revenue over ₹100 crores, bringing the total to 26.

    02

    Record Profitability and Margin Expansion

    The quarter saw an all-time high EBITDA margin of 28%, an increase of 184 basis points YoY and 138 basis points QoQ. Gross margin also improved to 68%, 166 basis points above the previous year, primarily due to overall mix change. Profit after tax stood at ₹1,571 crores, representing 22% of sales. However, management clarified that this 28% EBITDA margin is not sustainable for future quarters, attributing it to seasonal respiratory uptick and specific mix effects.

    03

    US Market Dynamics and Product Pipeline

    North America delivered a quarterly revenue rate of $226 million, with Albuterol market share reaching 21%. Key US product launches, Advair and Abraxane, are now slated for H2 FY26, with Advair from the US facility and Abraxane from the Goa facility post-approval. The delays are primarily due to regulatory clearance and manufacturing ramp-up. The company also has a pipeline of two to three respiratory assets expected in 18-24 months and other peptide assets, aiming for a significant ramp-up in its US respiratory portfolio.

    04

    Regulatory Updates and Quality Initiatives

    Cipla's Goa facility received a VAI Classification from the US FDA, a positive development. However, the Virgonagar and Medispray facilities were inspected, receiving eight and one 483 observations, respectively, with official classifications pending. Management emphasized its ongoing efforts to strengthen quality systems through improvements in practice, equipment, and talent to prevent future disruptions and ensure compliance.

    05

    Capital Allocation Strategy and Liquidity

    The company maintains a healthy net cash position of ₹8,947 crores as of December 31, 2024, against a debt of ₹466 crores. Cipla aims to address portfolio gaps through acquisitions, product licensing, and in-licensing in India, and by acquiring differentiated assets in the US and other attractive markets. The R&D investment for the quarter was ₹360 crores, approximately 5% of revenue, with a guidance of 5-6% for the future to support pipeline development. The company also reiterated its commitment to a dividend payout ratio of about 30%.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.